StreetInsider.com News Articles

Assembly Biosciences Announces Upcoming Investor Conference Presentations

Thu, 28 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences:

Jefferies 2026 Global Healthcare Conference
Date: June 3, 2026
Time: 4:20 p.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: June 8, 2026
Time: 8:40 a.m. ET

To register for either webcast, please visit the Events and Presentations section of Assembly Bio’s website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible

Assembly Biosciences Announces Upcoming Investor Conference Presentations

Thu, 28 May 2026 16:05:00 -0400

Jefferies 2026 Global Healthcare Conference
Date: June 3, 2026
Time: 4:20 p.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: June 8, 2026
Time: 8:40 a.m. ET

To register for either webcast, please visit the Events and Presentations section of Assembly Bio’s website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible

Form 4 ASSEMBLY BIOSCIENCES, For: May 26 Filed by: GILEAD SCIENCES, INC.

Wed, 27 May 2026 20:55:00 -0400

si-local-file:///var/storage/secattach/20260527/26559743.html

Form 4 ASSEMBLY BIOSCIENCES, For: May 26 Filed by: GILEAD SCIENCES, INC.

Wed, 27 May 2026 20:55:00 -0400

si-local-file:///var/storage/secattach/20260527/26559743.html

Form SCHEDULE 13D/A ASSEMBLY BIOSCIENCES, Filed by: GILEAD SCIENCES, INC.

Wed, 27 May 2026 20:51:00 -0400

si-local-file:///var/storage/secattach/20260527/26559739.html

Form SCHEDULE 13D/A ASSEMBLY BIOSCIENCES, Filed by: GILEAD SCIENCES, INC.

Wed, 27 May 2026 20:51:00 -0400

si-local-file:///var/storage/secattach/20260527/26559739.html

Form 8-K ASSEMBLY BIOSCIENCES, For: May 21

Tue, 26 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260526/26550031.html

Form 8-K ASSEMBLY BIOSCIENCES, For: May 21

Tue, 26 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260526/26550031.html

Assembly Biosciences completes $115 million stock offering

Tue, 26 May 2026 16:05:14 -0400

Assembly Biosciences Inc. (NASDAQ: ASMB) announced the completion of its underwritten public offering, raising approximately $115 million in gross proceeds before fees and expenses.

The biotechnology company sold 3,924,624 shares of common stock at $26.50 per share. The offering included the full exercise of underwriters' option to purchase an additional 566,040 shares. Assembly Biosciences also issued pre-funded warrants to an existing investor for 415,000 shares at $26.499 per warrant, representing the share price minus a $0.001 exercise price.

The company stated it plans to use net proceeds to fund clinical development of pipeline candidates and general corporate purposes. Assembly Biosciences develops therapeutics

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Tue, 26 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shares of common stock. In addition, and in lieu of common stock, Assembly Bio sold to a certain existing investor pre-funded warrants to purchase up to

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Tue, 26 May 2026 16:05:00 -0400

Form 424B5 ASSEMBLY BIOSCIENCES,

Tue, 26 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26545195.html

Form 424B5 ASSEMBLY BIOSCIENCES,

Tue, 26 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26545195.html

Form 424B5 ASSEMBLY BIOSCIENCES,

Fri, 22 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26541365.html

Form 424B5 ASSEMBLY BIOSCIENCES,

Fri, 22 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26541365.html

Form 8-K ASSEMBLY BIOSCIENCES, For: May 22

Fri, 22 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260522/26538498.html

Form 8-K ASSEMBLY BIOSCIENCES, For: May 22

Fri, 22 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260522/26538498.html

Assembly Biosciences prices $100 million stock offering at $26.50 per share

Fri, 22 May 2026 07:05:15 -0400

Assembly Biosciences Inc. (NASDAQ: ASMB) announced the pricing of an underwritten offering of 3,358,602 shares of common stock at $26.50 per share and pre-funded warrants to purchase up to 415,000 shares at $26.499 per warrant. The biotechnology company expects gross proceeds of approximately $100 million before deducting underwriting discounts and other offering expenses.

The offering includes participation from new and existing investors, including Gilead Sciences Inc., Commodore Capital, Farallon Capital Management, Seven Fleet Capital, Sirenia Capital Management LP, Columbia Threadneedle Investments, Paradigm BioCapital Advisors, Squadron Capital Management and other healthcare-focused investors.